Senti Biosciences Holdings, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $22.0K | $0 | $2.6M | $4.3M | $2.8M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $37.6M | $34.4M | $32.2M | $28.1M | $22.0M |
| SG&A Expense | $26.2M | $26.4M | $37.2M | $38.2M | $21.3M |
| Operating Income | $-68.8M | $-61.0M | $-92.7M | $-62.1M | $-40.4M |
| Operating Margin | -312,631.8% | — | -3,620.7% | -1,448.5% | -1,464.9% |
| Interest Expense | — | — | — | — | — |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | — | — | $0 |
| Net Income | $-61.4M | $-52.8M | $-71.1M | $-58.2M | $-55.3M |
| Net Margin | -279,263.6% | — | -2,774.6% | -1,358.1% | -2,003.6% |
| EPS (Basic) | $-2.73 | $-2.41 | $-3.20 | $-0.45 | $-0.42 |
| EPS (Diluted) | $-2.73 | $-2.41 | $-3.20 | $-0.45 | $-0.42 |
| Shares Outstanding (Basic) | 22.5M | 23.0M | 22.2M | 130.6M | 131.1M |
| Shares Outstanding (Diluted) | 22.5M | 23.0M | 22.2M | 130.6M | 131.1M |
| Dividends Per Share | — | — | — | — | — |